Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Onikoroshi LLC has 1 pending office action in Biotechnology & Pharmaceuticals. This single action is handled by 1 distinct examiner, KRIANGCHAIVECH, KETTIP, in 1 distinct art unit. This is the smallest possible prosecution footprint, with only 1 pending office action currently active at the USPTO. The presence of only 1 pending office action suggests a very early or highly selective entry into the patent system.
KRIANGCHAIVECH, KETTIP is the busiest examiner by default, holding the 1 pending office action. For Onikoroshi LLC, the entire prosecution experience is currently defined by this one examiner and one art unit. There is no other pending data to provide a broader context for their USPTO interactions. Practitioners must ensure that the arguments presented to KRIANGCHAIVECH, KETTIP are highly refined, as there are no other pending cases to provide alternative paths to allowance. The concentration in 1 distinct art unit further emphasizes the specialized nature of the technology currently under review. Without additional pending matters, the company's immediate patent success relies entirely on the outcome of this single interaction.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| KRIANGCHAIVECH, KETTIP | 1 | 19.0% | +28.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19303223 | PERSONALIZED WELLNESS SYSTEMS AND METHODS OF USE | KRIANGCHAIVECH, KETTIP | 30d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19303223 | PERSONALIZED WELLNESS SYSTEMS AND METHODS OF USE | KRIANGCHAIVECH, KETTIP | 30d overdue |
| Art Unit | Apps |
|---|---|
| 1686 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19303223 | PERSONALIZED WELLNESS SYSTEMS AND METHODS OF USE | KRIANGCHAIVECH, KETTIP | 1686 | §101§103DP | Final Rejection | 30d overdue | Pending | Aug 18, 2025 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialOnikoroshi LLC has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Kettip Kriangchaivech has the most, with 1 of Onikoroshi LLC's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
